FindTrial
Sign In

Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo

Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo - MAP-J

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010596
Enrollment
40
Registered
2013-05-01
Start date
2013-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Memantine preceding arm Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months. Amantadine preceding arm Titrate the amantadine, admi

Sponsors

Department of Neurology, Juntendo University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1)dyskinesia with wearing off 2)Cognitive dysfunction(Moca-J point less than 26)

Exclusion criteria

Exclusion criteria: 1)Patient has been administered amantadine or memantine already. 2)Patient dose needs to be changed during the study period cholinesterase inhibitors. 3)Patients scheduled to come into effect during the study period deep brain stimulation surgery(DBS). 4)Women and lactating women might be pregnant, are pregnant. 5)In addition, patients attending physician was deemed inappropriate.

Design outcomes

Primary

MeasureTime frame
Improvement of dyskinesias—

Secondary

MeasureTime frame
Changes in cognitive function score Changes in REM sleep behavior disorder—

Countries

Japan

Contacts

Public ContactTaku Hatano

Juntendo University School of Medicine Department of Neurology

thatano@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026